• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Distribution and Temporal Dynamics of Plasmodium falciparum Chloroquine Resistance Transporter Mutations Associated With Piperaquine Resistance in Northern Cambodia.柬埔寨北部与哌喹耐药相关的恶性疟原虫氯喹耐药转运体突变的分布和时间动态。
J Infect Dis. 2021 Sep 17;224(6):1077-1085. doi: 10.1093/infdis/jiab055.
2
Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization.哌喹耐药柬埔寨疟原虫临床分离株的体外基因和表型特征。
Malar J. 2020 Jul 25;19(1):269. doi: 10.1186/s12936-020-03339-w.
3
Evaluations of candidate markers of dihydroartemisinin-piperaquine resistance in Plasmodium falciparum isolates from the China-Myanmar, Thailand-Myanmar, and Thailand-Cambodia borders.评价来自中缅、泰缅和泰柬边境地区恶性疟原虫分离株的双氢青蒿素-哌喹耐药候选标志物。
Parasit Vectors. 2022 Apr 12;15(1):130. doi: 10.1186/s13071-022-05239-1.
4
Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine.出现的东南亚 PfCRT 突变使恶性疟原虫对一线抗疟药哌喹产生耐药性。
Nat Commun. 2018 Aug 17;9(1):3314. doi: 10.1038/s41467-018-05652-0.
5
Prevalence and characterization of piperaquine, mefloquine and artemisinin derivatives triple-resistant Plasmodium falciparum in Cambodia.柬埔寨哌喹、甲氟喹和青蒿素衍生物三重耐药恶性疟原虫的流行情况及特征。
J Antimicrob Chemother. 2023 Feb 1;78(2):411-417. doi: 10.1093/jac/dkac403.
6
A genetic cross reveals the contributions of and to piperaquine drug resistance.一次基因杂交揭示了[相关基因]对哌喹耐药性的影响。 (注:原文中“and”前面应该缺失了一些内容,这里根据语境补充了“[相关基因]”,以便使译文更通顺,但严格按照要求,应按照你提供的原文准确翻译为:一次基因杂交揭示了和对哌喹耐药性的影响。不过这样的译文不太符合正常表达习惯。)
mBio. 2024 Jul 17;15(7):e0080524. doi: 10.1128/mbio.00805-24. Epub 2024 Jun 24.
7
A Variant PfCRT Isoform Can Contribute to Resistance to the First-Line Partner Drug Piperaquine.一种变异的疟原虫氯喹抗性转运蛋白(PfCRT)异构体可能导致对一线联合用药磷酸哌喹产生耐药性。
mBio. 2017 May 9;8(3):e00303-17. doi: 10.1128/mBio.00303-17.
8
Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates.恶性疟原虫氯喹耐药转运蛋白(PfCRT)基因突变的流行情况及其与非洲恶性疟原虫分离株体外常见抗疟药物敏感性的关系。
Malar J. 2020 Jun 5;19(1):201. doi: 10.1186/s12936-020-03281-x.
9
Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand.在泰国东北部出现哌喹耐药性期间恶性疟原虫表型和基因型耐药谱。
Sci Rep. 2021 Jun 28;11(1):13419. doi: 10.1038/s41598-021-92735-6.
10
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.中医疗法治疗失败的决定因素:柬埔寨、泰国和越南间日疟原虫疟疾的前瞻性临床、药理学和遗传学研究。
Lancet Infect Dis. 2019 Sep;19(9):952-961. doi: 10.1016/S1473-3099(19)30391-3. Epub 2019 Jul 22.

引用本文的文献

1
The plasmepsin-piperaquine paradox persists in Plasmodium falciparum.恶性疟原虫中血浆蛋白酶-哌喹矛盾现象仍然存在。
PLoS Pathog. 2025 Jul 28;21(7):e1012779. doi: 10.1371/journal.ppat.1012779. eCollection 2025 Jul.
2
Malaria: past, present, and future.疟疾:过去、现在与未来。
Signal Transduct Target Ther. 2025 Jun 17;10(1):188. doi: 10.1038/s41392-025-02246-3.
3
Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.撒哈拉以南非洲疟疾感染人群中恶性疟原虫K13基因对青蒿素联合疗法及相关药物的新出现突变
Parasites Hosts Dis. 2025 May;63(2):109-122. doi: 10.3347/PHD.24053. Epub 2025 May 26.
4
Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana.圭亚那疟原虫无性系谱系的时空动态。
PLoS Pathog. 2024 Jun 13;20(6):e1012013. doi: 10.1371/journal.ppat.1012013. eCollection 2024 Jun.
5
Characterisation of populations at risk of sub-optimal dosing of artemisinin-based combination therapy in Africa.非洲基于青蒿素联合疗法用药剂量不足风险人群的特征分析。
PLOS Glob Public Health. 2023 Dec 1;3(12):e0002059. doi: 10.1371/journal.pgph.0002059. eCollection 2023.
6
Malaria Control by Mass Drug Administration With Artemisinin Plus Piperaquine on Grande Comore Island, Union of Comoros.在科摩罗联盟大科摩罗岛通过大规模药物管理使用青蒿素加哌喹控制疟疾
Open Forum Infect Dis. 2023 Feb 14;10(3):ofad076. doi: 10.1093/ofid/ofad076. eCollection 2023 Mar.
7
Short tandem repeat polymorphism in the promoter region of cyclophilin 19B drives its transcriptional upregulation and contributes to drug resistance in the malaria parasite Plasmodium falciparum.短串联重复多态性在环孢素 19B 启动子区域驱动其转录上调,并有助于疟原虫恶性疟原虫的耐药性。
PLoS Pathog. 2023 Jan 25;19(1):e1011118. doi: 10.1371/journal.ppat.1011118. eCollection 2023 Jan.
8
Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials.突变型 PfCRT 可降低非洲恶性疟原虫的适应度并增加对其他抗疟药物的敏感性,从而介导哌喹耐药性。
J Infect Dis. 2022 Nov 28;226(11):2021-2029. doi: 10.1093/infdis/jiac365.
9
Plasmodium falciparum resistance to artemisinin-based combination therapies.恶性疟原虫对青蒿素类复方疗法的抗药性。
Curr Opin Microbiol. 2022 Oct;69:102193. doi: 10.1016/j.mib.2022.102193. Epub 2022 Aug 22.
10
Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.恶性疟原虫对青蒿素类复方药物的抗药性:出现、机制和展望。
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:102-118. doi: 10.1016/j.ijpddr.2021.05.007. Epub 2021 May 26.

本文引用的文献

1
Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization.哌喹耐药柬埔寨疟原虫临床分离株的体外基因和表型特征。
Malar J. 2020 Jul 25;19(1):269. doi: 10.1186/s12936-020-03339-w.
2
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.三药联合疗法与青蒿素类复方疗法治疗无并发症恶性疟原虫疟疾的比较:一项多中心、开放标签、随机临床试验。
Lancet. 2020 Apr 25;395(10233):1345-1360. doi: 10.1016/S0140-6736(20)30552-3. Epub 2020 Mar 11.
3
Structure and drug resistance of the Plasmodium falciparum transporter PfCRT.恶性疟原虫转运蛋白 PfCRT 的结构与耐药性。
Nature. 2019 Dec;576(7786):315-320. doi: 10.1038/s41586-019-1795-x. Epub 2019 Nov 27.
4
Atovaquone-Proguanil in Combination With Artesunate to Treat Multidrug-Resistant Malaria in Cambodia: An Open-Label Randomized Trial.阿托伐醌-氯胍联合青蒿琥酯治疗柬埔寨耐多药疟疾:一项开放标签随机试验。
Open Forum Infect Dis. 2019 Sep 4;6(9):ofz314. doi: 10.1093/ofid/ofz314. eCollection 2019 Sep.
5
Plasmodium falciparum resistance to piperaquine driven by PfCRT.由恶性疟原虫氯喹抗性转运蛋白(PfCRT)驱动的恶性疟原虫对哌喹的抗性。
Lancet Infect Dis. 2019 Nov;19(11):1168-1169. doi: 10.1016/S1473-3099(19)30543-2.
6
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.中医疗法治疗失败的决定因素:柬埔寨、泰国和越南间日疟原虫疟疾的前瞻性临床、药理学和遗传学研究。
Lancet Infect Dis. 2019 Sep;19(9):952-961. doi: 10.1016/S1473-3099(19)30391-3. Epub 2019 Jul 22.
7
Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study.东南亚耐多药疟疾的演变和扩散:一项基于基因组流行病学的研究。
Lancet Infect Dis. 2019 Sep;19(9):943-951. doi: 10.1016/S1473-3099(19)30392-5. Epub 2019 Jul 22.
8
Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine.出现的东南亚 PfCRT 突变使恶性疟原虫对一线抗疟药哌喹产生耐药性。
Nat Commun. 2018 Aug 17;9(1):3314. doi: 10.1038/s41467-018-05652-0.
9
Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity.恶性疟原虫氯喹抗性转运蛋白中的一种新型突变与哌喹敏感性降低的关联。
J Infect Dis. 2017 Aug 15;216(4):468-476. doi: 10.1093/infdis/jix334.
10
The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study.大湄公河次区域青蒿素耐药恶性疟原虫的传播:一项分子流行病学观察性研究。
Lancet Infect Dis. 2017 May;17(5):491-497. doi: 10.1016/S1473-3099(17)30048-8. Epub 2017 Feb 2.

柬埔寨北部与哌喹耐药相关的恶性疟原虫氯喹耐药转运体突变的分布和时间动态。

Distribution and Temporal Dynamics of Plasmodium falciparum Chloroquine Resistance Transporter Mutations Associated With Piperaquine Resistance in Northern Cambodia.

机构信息

Malaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

出版信息

J Infect Dis. 2021 Sep 17;224(6):1077-1085. doi: 10.1093/infdis/jiab055.

DOI:10.1093/infdis/jiab055
PMID:33528566
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8448439/
Abstract

BACKGROUND

Newly emerged mutations within the Plasmodium falciparum chloroquine resistance transporter (PfCRT) can confer piperaquine resistance in the absence of amplified plasmepsin II (pfpm2). In this study, we estimated the prevalence of co-circulating piperaquine resistance mutations in P. falciparum isolates collected in northern Cambodia from 2009 to 2017.

METHODS

The sequence of pfcrt was determined for 410 P. falciparum isolates using PacBio amplicon sequencing or whole genome sequencing. Quantitative polymerase chain reaction was used to estimate pfpm2 and pfmdr1 copy number.

RESULTS

Newly emerged PfCRT mutations increased in prevalence after the change to dihydroartemisinin-piperaquine in 2010, with >98% of parasites harboring these mutations by 2017. After 2014, the prevalence of PfCRT F145I declined, being outcompeted by parasites with less resistant, but more fit PfCRT alleles. After the change to artesunate-mefloquine, the prevalence of parasites with amplified pfpm2 decreased, with nearly half of piperaquine-resistant PfCRT mutants having single-copy pfpm2.

CONCLUSIONS

The large proportion of PfCRT mutants that lack pfpm2 amplification emphasizes the importance of including PfCRT mutations as part of molecular surveillance for piperaquine resistance in this region. Likewise, it is critical to monitor for amplified pfmdr1 in these PfCRT mutants, as increased mefloquine pressure could lead to mutants resistant to both drugs.

摘要

背景

疟原虫氯喹耐药转运蛋白(PfCRT)中出现的新突变可在没有扩增的质体蛋白酶 II(pfpm2)的情况下赋予哌喹耐药性。在这项研究中,我们估计了 2009 年至 2017 年在柬埔寨北部采集的疟原虫分离株中共同循环的哌喹耐药突变的流行率。

方法

使用 PacBio 扩增子测序或全基因组测序确定了 410 株疟原虫PfCRT 的序列。定量聚合酶链反应用于估计 pfpm2 和 pfmdr1 拷贝数。

结果

2010 年改用二氢青蒿素-哌喹后,新出现的 PfCRT 突变的流行率增加,到 2017 年,超过 98%的寄生虫携带这些突变。2014 年后,PfCRT F145I 的流行率下降,被耐药性较低但更适合 PfCRT 等位基因的寄生虫所取代。改用青蒿琥酯-甲氟喹后,携带扩增 pfpm2 的寄生虫的流行率下降,近一半的哌喹耐药 PfCRT 突变体只有单拷贝 pfpm2。

结论

缺乏 pfpm2 扩增的 PfCRT 突变体的比例很大,这强调了在该地区将 PfCRT 突变作为哌喹耐药性分子监测的一部分的重要性。同样,监测这些 PfCRT 突变体中扩增的 pfmdr1 也至关重要,因为增加的甲氟喹压力可能导致对这两种药物都耐药的突变体。